967 related articles for article (PubMed ID: 25754658)
21. Utility and prognostic value of
Aljama MA; Sidiqi MH; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Rajkumar SV; Kumar SK
Am J Hematol; 2018 Dec; 93(12):1518-1523. PubMed ID: 30194770
[TBL] [Abstract][Full Text] [Related]
22. Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.
Sauter CS; Lechner L; Scordo M; Zheng J; Devlin SM; Fleming SE; Castro-Malaspina H; Moskowitz CH
Biol Blood Marrow Transplant; 2014 Jun; 20(6):881-4. PubMed ID: 24534109
[TBL] [Abstract][Full Text] [Related]
23. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.
Franssen LE; Raymakers RA; Buijs A; Schmitz MF; van Dorp S; Mutis T; Lokhorst HM; van de Donk NW
Eur J Haematol; 2016 Nov; 97(5):479-488. PubMed ID: 27028304
[TBL] [Abstract][Full Text] [Related]
24. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
[TBL] [Abstract][Full Text] [Related]
25. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].
Ying ZT; Mi L; Wang XJ; Zhang YW; Yang Z; Song YQ; Wang XP; Zheng W; Lin NJ; Tu MF; Xie Y; Ping LY; Zhang C; Liu WP; Deng LJ; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):382-386. PubMed ID: 29779346
[No Abstract] [Full Text] [Related]
27. Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience.
Minnema MC; van Dorp S; van de Donk NW; Schouten F; Kersten MJ; Coenen JL; Schouten H; Zweegman S; Schaafsma R; Lokhorst HM
Bone Marrow Transplant; 2011 Feb; 46(2):244-9. PubMed ID: 20400982
[TBL] [Abstract][Full Text] [Related]
28. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
29. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
[TBL] [Abstract][Full Text] [Related]
30. Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.
Cohen JB; Hall NC; Ruppert AS; Jones JA; Porcu P; Baiocchi R; Christian BA; Penza S; Benson DM; Flynn J; Andritsos LA; Devine SM; Blum KA
Bone Marrow Transplant; 2013 Sep; 48(9):1212-7. PubMed ID: 23584442
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
32. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.
Shigematsu A; Kobayashi N; Yasui H; Shindo M; Kakinoki Y; Koda K; Iyama S; Kuroda H; Tsutsumi Y; Imamura M; Teshima T
Biol Blood Marrow Transplant; 2014 Jun; 20(6):801-5. PubMed ID: 24565990
[TBL] [Abstract][Full Text] [Related]
33. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome.
Nakai K; Kanda Y; Fukuhara S; Sakamaki H; Okamoto S; Kodera Y; Tanosaki R; Takahashi S; Matsushima T; Atsuta Y; Hamajima N; Kasai M; Kato S
Leukemia; 2005 Mar; 19(3):396-401. PubMed ID: 15674354
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Baseline
Moon SH; Choi WH; Yoo IR; Lee SJ; Paeng JC; Jeong SY; Lee SW; Kim K; Choi JY
Korean J Radiol; 2018; 19(3):481-488. PubMed ID: 29713226
[TBL] [Abstract][Full Text] [Related]
35. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
36. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
37. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma.
Haznedar R; Akı SZ; Akdemir OU; Ozkurt ZN; Ceneli O; Yağcı M; Sucak GT; Unlü M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1046-53. PubMed ID: 21287167
[TBL] [Abstract][Full Text] [Related]
38. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
Donato ML; Siegel DS; Vesole DH; McKiernan P; Nyirenda T; Pecora AL; Baker M; Goldberg SL; Mato A; Goy A; Rowley SD
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1211-6. PubMed ID: 24792872
[TBL] [Abstract][Full Text] [Related]
39. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
Shimoni A; Hardan I; Ayuk F; Schilling G; Atanackovic D; Zeller W; Yerushalmi R; Zander AR; Kroger N; Nagler A
Cancer; 2010 Aug; 116(15):3621-30. PubMed ID: 20564132
[TBL] [Abstract][Full Text] [Related]
40. Autologous and allogeneic transplantation for multiple myeloma at a single centre.
Couban S; Stewart AK; Loach D; Panzarella T; Meharchand J
Bone Marrow Transplant; 1997 Apr; 19(8):783-9. PubMed ID: 9134169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
